1FW 1645



PATENT 2543-1-041PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Katherine Ann Vousden

SERIAL NO. :

10/537,583

EXAMINER:

Oluwatosin A. Ogunbiyi

FILED

December 14, 2005

ART UNIT

1645

FOR

CCA1 AS AN ANTIFUNGAL TARGET

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on ___SEPTEMBER 28, 2006 .

Karen Garipoli
(Name of Depositor.)

(Signature and Date)

RESPONSE TO REQUIREMENT FOR RESTRICTION UNDER 35 U.S.C. §121

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Dear Sir:

This is in response to the Requirement for Restriction imposed by the Office Action of August 29, 2006.

As understood, the claims have been determined to be distinct in accordance with the following groups and under 37 CFR 1.499.

PATENT 2543-1-041PCT/US

Group I - Claims 1-11 and 17 drawn to a method of screening or testing for candidate antifungal compounds that impair ATP(CTP);tRNA nucleotidyltransferase enzyme (CCA1) function.

Group II - Claims 14-16 and 18-22 drawn to a method for the treatment or prevention of fungal infections in a host.

Applicants elect to prosecute herewith the claims of Group I, namely claims 1-11 and 17, without traverse.

Further and favorable action on the merits is courteously solicited.

Respectfully submitted,

DAVID A. JACKSON Attorney for Applicant(s)

Registration No. 26,742

KLAUBER & JACKSON, LLC 411 Hackensack Avenue, 4th Floor Hackensack, NJ 07601 (201) 487-5800